615 results match your criteria Pathophysiology and Treatment of Migraine and Related Headache


CALCA and TRPV1 genes polymorphisms are related to a good outcome in female chronic migraine patients treated with OnabotulinumtoxinA.

J Headache Pain 2019 Apr 23;20(1):39. Epub 2019 Apr 23.

Headache Unit, Neurology Department, Hospital Clínico Universitario de Valladolid, Avda. Ramón y Cajal 3, 47005, Valladolid, Spain.

Background: Some variables have been proposed as predictors of efficacy of OnabotulinumtoxinA in chronic migraine patients, but data available are inconclusive. We aimed to analyse the influence of single nucleotide polymorphisms in the response to OnabotulinumtoxinA.

Methods: We included 156 female patients treated with OnabotulinumtoxinA accordingly to PREEMPT paradigm in three headache units. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-019-0989-9DOI Listing

Pathophysiological Mechanisms in Migraine and the Identification of New Therapeutic Targets.

CNS Drugs 2019 Apr 15. Epub 2019 Apr 15.

Department of Clinical and Experimental Research, Glostrup Research Institute, Copenhagen University Hospital, Rigshospitalet-Glostrup, Nordstjernevej 42, 2600, Glostrup, Denmark.

Migraine is a strongly disabling disease characterized by a unilateral throbbing headache lasting for up to 72 h for each individual attack. There have been many theories on the pathophysiology of migraine throughout the years. Currently, the neurovascular theory dominates, suggesting clear involvement of the trigeminovascular system. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40263-019-00630-6
Publisher Site
http://dx.doi.org/10.1007/s40263-019-00630-6DOI Listing
April 2019
1 Read

Safety and Tolerability of Fremanezumab for the Prevention of Migraine: A Pooled Analysis of Phases 2b and 3 Clinical Trials.

Headache 2019 Apr 12. Epub 2019 Apr 12.

Teva Pharmaceuticals, Frazer, PA, USA.

Objective: Presentation of pooled analysis of safety data for fremanezumab in patients with chronic (CM) or episodic migraine (EM) from 4 placebo-controlled phase 2b and phase 3 studies.

Background: There is a need for an effective, safe, and well-tolerated preventive therapy that specifically targets the pathophysiology of migraine to reduce the frequency and severity of migraine attacks in patients with CM or EM who experience 4 or more migraine days per month. Fremanezumab is a fully humanized monoclonal antibody that targets calcitonin gene-related peptide, a neuropeptide involved in the pathophysiology of migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13534DOI Listing
April 2019
1 Read

TRP Channels and Migraine: Recent Developments and New Therapeutic Opportunities.

Pharmaceuticals (Basel) 2019 Apr 9;12(2). Epub 2019 Apr 9.

School of Behavioral and Brain Sciences, Center for Advanced Pain Studies, The University of Texas at Dallas, Richardson, TX 75080, USA.

Migraine is the second-most disabling disease worldwide, and the second most common neurological disorder. Attacks can last many hours or days, and consist of multiple symptoms including headache, nausea, vomiting, hypersensitivity to stimuli such as light and sound, and in some cases, an aura is present. Mechanisms contributing to migraine are still poorly understood. Read More

View Article

Download full-text PDF

Source
https://www.mdpi.com/1424-8247/12/2/54
Publisher Site
http://dx.doi.org/10.3390/ph12020054DOI Listing
April 2019
2 Reads

Dural calcitonin gene-related peptide produces female-specific responses in rodent migraine models.

J Neurosci 2019 Apr 8. Epub 2019 Apr 8.

School of Behavioral and Brain Sciences, Center for Advanced Pain Studies, University of Texas at Dallas. 800 W. Campbell Rd. Richardson, TX 75080

Migraine is the second leading cause for disability worldwide and the most common neurological disorder. It is also three times more common in women; reasons for this sex difference are not known. Using preclinical behavioral models of migraine, we show that application of CGRP to the rat dura mater produces cutaneous periorbital hypersensitivity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1523/JNEUROSCI.0364-19.2019DOI Listing

Some aspects on the pathophysiology of migraine and a review of device therapies for migraine and cluster headache.

Neurol Sci 2019 Mar 25. Epub 2019 Mar 25.

Department of Medicine, Institute of Clinical Sciences, Lund University, Lund, Sweden.

Migraine is a common, severe disease, affecting the brain and blood vessels, causing much pain, time missed from work and family, and severe disability. It affects approximately 12% of most Western populations studied and affects women three times more than men. Cluster headache is a much less common dysfunction of the hypothalamus, involving the sphenopalatine ganglion and other areas; it causes more frequent, shorter, and even more intense pain than migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s10072-019-03828-0DOI Listing
March 2019
1 Read

CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?

J Headache Pain 2019 Mar 12;20(1):27. Epub 2019 Mar 12.

UOC Neurologia e Stroke Unit, Ospedale SS Filippo e Nicola, Avezzano, Italy.

Calcitonin gene-related peptide (CGRP) is a neuropeptide with a pivotal role in the pathophysiology of migraine. Blockade of CGRP is a new therapeutic target for patients with migraine. CGRP and its receptors are distributed not only in the central and peripheral nervous system but also in the cardiovascular system, both in blood vessels and in the heart. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-019-0979-yDOI Listing
March 2019
1 Read

Predictive value of laboratory parameters in childhood migraine.

Acta Neurol Belg 2019 Mar 6. Epub 2019 Mar 6.

Department of Family Medicine, Medical School of Adiyaman University, Adiyaman, Turkey.

Migraine is a neurovascular disease characterized by inflammation of the cerebral and extra cerebral vessels and appears in the form of attacks. Although the pathophysiology of migraine is not fully known, the data obtained because of long-term studies reliably support the presence of a potential relationship between migraine pathogenesis and platelet biology. The aim of this study was to investigate the effect of migraine on MPV and other blood parameters as well as the relationship between the hematologic parameters and characteristics of the headache and whether they possess diagnostic value as inflammation and platelet biology play a fundamental role in the disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13760-019-01106-6DOI Listing
March 2019
4 Reads

Plasma Calcitonin Gene-Related Peptide: A Potential Biomarker for Diagnosis and Therapeutic Responses in Pediatric Migraine.

Front Neurol 2019 24;10:10. Epub 2019 Jan 24.

Clinical Center for Neuroscience and Behavior, National Taiwan University Hospital, Taipei, Taiwan.

Plasma calcitonin gene-related peptide (CGRP) plays a key role in the migraine pathophysiology. This study aimed to investigate its role in predicting diagnosis and outcome of pharmacotherapy in pediatric migraine. We prospectively recruited 120 subjects, who never took migraine-preventive agents in a pediatric clinic, including 68 patients with migraine, 30 with non-migraine headache (NM), and 22 non-headache (NH) age-matched controls. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fneur.2019.00010DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6353836PMC
January 2019
3 Reads

Pharmacokinetics and pharmacodynamics of new acute treatments for migraine.

Expert Opin Drug Metab Toxicol 2019 Mar 12;15(3):189-198. Epub 2019 Feb 12.

d Regional Referral Headache Centre, Sant'Andrea Hospital, Department of Clinical and Molecular Medicine , Sapienza University of Rome , Rome , Italy.

Introduction: Recommended medications for the acute treatment of migraine encompass triptans, nonsteroidal anti-inflammatory drugs (NSAIDs), and analgesics. While it is true that triptans have been the first successful mechanism-driven treatment in the field, recently, new targets involved in migraine pathogenesis have emerged and new drug classes have been studied for migraine attack therapy. Areas covered: Pharmacodynamics and pharmacokinetics of the new acute treatments of migraine (i. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17425255.2019.1
Publisher Site
http://dx.doi.org/10.1080/17425255.2019.1578749DOI Listing
March 2019
13 Reads

Pain-related avoidance and endurance behaviour in migraine: an observational study.

J Headache Pain 2019 Jan 18;20(1). Epub 2019 Jan 18.

Department of Neurology, Ludwig Maximilians University, Marchioninistr. 15, 81377, Munich, Germany.

Background: The role of avoidance and endurance behaviour is well established in chronic musculoskeletal pain, but less is known about its significance in migraine.

Methods: The Avoidance-Endurance Questionnaire behavioural subscales, the Pain Disability Index (PDI), the Migraine Disability Assessment Scale (MIDAS) and the Hospital Anxiety and Depression Scale (HADS) were obtained from 128 migraine patients (90 episodic, 38 chronic). Sixty nine of them were re-evaluated after 3-6 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-019-0962-7DOI Listing
January 2019
2 Reads

Efficacy and safety of exogenous ketone bodies for preventive treatment of migraine: A study protocol for a single-centred, randomised, placebo-controlled, double-blind crossover trial.

Trials 2019 Jan 17;20(1):61. Epub 2019 Jan 17.

Division of Neuropaediatrics, University of Basel Children's Hospital, University of Basel, Spitalstrasse 33, Postfach, 4056, Basel, Switzerland.

Background: Currently available prophylactic migraine treatment options are limited and are associated with many, often intolerable, side-effects. Various lines of research suggest that abnormalities in energy metabolism are likely to be part of migraine pathophysiology. Previously, a ketogenic diet (KD) has been reported to lead to a drastic reduction in migraine frequency. Read More

View Article

Download full-text PDF

Source
https://trialsjournal.biomedcentral.com/articles/10.1186/s13
Publisher Site
http://dx.doi.org/10.1186/s13063-018-3120-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6337840PMC
January 2019
13 Reads

Abnormal functional connectivity under somatosensory stimulation in migraine: a multi-frequency magnetoencephalography study.

J Headache Pain 2019 Jan 9;20(1). Epub 2019 Jan 9.

Department of Neurology, The Affiliated Brain Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Background: Although altered neural networks have been demonstrated in recent MEG (magnetoencephalography) research in migraine patients during resting state, it is unknown whether this alteration can be detected in task-related networks. The present study aimed to investigate the abnormalities of the frequency-specific somatosensory-related network in migraine patients by using MEG.

Methods: Twenty-two migraineurs in the interictal phase and twenty-two sex- and age-matched healthy volunteers were studied using a whole-head magnetoencephalography (MEG) system. Read More

View Article

Download full-text PDF

Source
https://thejournalofheadacheandpain.biomedcentral.com/articl
Publisher Site
http://dx.doi.org/10.1186/s10194-019-0958-3DOI Listing
January 2019
3 Reads
2.801 Impact Factor

Migraine Progression: A Systematic Review.

Headache 2019 Mar 27;59(3):306-338. Epub 2018 Dec 27.

Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA.

Background: Migraine is a common and often debilitating neurological disease. It can be divided into episodic and chronic subforms based on the number of monthly headache days. Because only a subset of individuals with episodic migraine (EM) progress to chronic migraine (CM) over any given time period, understanding the factors that predict the new onset of CM or "migraine progression" may provide insights into the mechanisms, pathophysiology, prevention, and treatment of CM. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/head.13459
Publisher Site
http://dx.doi.org/10.1111/head.13459DOI Listing
March 2019
22 Reads

Circulating nociceptin and CGRP in medication-overuse headache.

Acta Neurol Scand 2019 Mar 11;139(3):269-275. Epub 2018 Dec 11.

Department of Neurology, Rigshospitalet-Glostrup, Danish Headache Center, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.

Background: Previous studies found low serum levels of nociceptin in migraine patients but high serum levels of calcitonin gene-related peptide (CGRP). CGRP can elicit migraine-like headache. Medication-Overuse Headache (MOH) often has migraine features and can mimic chronic migraine. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/ane.13053
Publisher Site
http://dx.doi.org/10.1111/ane.13053DOI Listing
March 2019
17 Reads

Increased susceptibility to cortical spreading depression and epileptiform activity in a mouse model for FHM2.

Sci Rep 2018 Nov 16;8(1):16959. Epub 2018 Nov 16.

Dominick P. Purpura Department of Neuroscience, Albert Einstein College of Medicine, 1410 Pelham Parkway South, Bronx, NY, 10461, USA.

Migraine is a highly prevalent, debilitating, episodic headache disorder affecting roughly 15% of the population. Familial hemiplegic migraine type 2 (FHM2) is a rare subtype of migraine caused by mutations in the ATP1A2 gene, encoding the α isoform of the Na/K-ATPase, predominantly expressed in astrocytes. Differential comorbidities such as epilepsy and psychiatric disorders manifest in patients. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41598-018-35285-8
Publisher Site
http://dx.doi.org/10.1038/s41598-018-35285-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6240030PMC
November 2018
24 Reads

Perampanel inhibits calcitonin gene-related peptide release from rat brainstem in vitro.

J Headache Pain 2018 Nov 12;19(1):107. Epub 2018 Nov 12.

Institute of Pharmacology, Fondazione Policlinico Universitario A. Gemelli IRCSS, Roma - Università Cattolica del Sacro Cuore, Largo Francesco Vito 1, 00168, Rome, Italy.

Background: Perampanel is a novel antiepileptic drug acting via non-competitive antagonism on glutamatergic AMPA receptors, and the subsequent inhibition of ion calcium influx. Since it was recently postulated that the antagonists of glutamate receptors might play a role in the treatment of migraine, in this study we investigated the putative anti-migraine activity of perampanel in an in vitro animal model involving the static incubation of rat brainstem explants and the subsequent measurement of immune-reactive calcitonin gene-related peptide released into the incubation medium.

Methods: Acute rat brainstem explants were incubated in plain medium or in medium containing graded concentrations of perampanel. Read More

View Article

Download full-text PDF

Source
https://thejournalofheadacheandpain.biomedcentral.com/articl
Publisher Site
http://dx.doi.org/10.1186/s10194-018-0940-5DOI Listing
November 2018
19 Reads

Fremanezumab: First Global Approval.

Authors:
Sheridan M Hoy

Drugs 2018 Nov;78(17):1829-1834

Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.

Fremanezumab-vfrm (hereafter referred to as fremanezumab) [AJOVY™] is a fully humanized monoclonal antibody (IgG2Δa) developed by Teva Pharmaceuticals to selectively target calcitonin gene-related peptide (a vasodilatory neuropeptide involved in the pathophysiology of migraine). Its use has been associated with significant reductions in migraine frequency, the requirement for acute headache medication use and headache-related disability compared with placebo in multinational, phase III studies, and in September 2018 fremanezumab was approved by the US FDA for the preventive treatment of migraine in adults. A regulatory assessment for fremanezumab as a preventive treatment of migraine in adults is underway in the EU. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s40265-018-1004-5
Publisher Site
http://dx.doi.org/10.1007/s40265-018-1004-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422958PMC
November 2018
12 Reads

Migraine Headache: Updates and Future Developments.

Mayo Clin Proc 2018 Nov;93(11):1648-1653

Department of Neurology, Mayo Clinic, Jacksonville, FL.

Migraine is a common disabling condition that is frequently managed by primary care providers. In recent years, the growing array of migraine therapies has added complexity to patient care. This article serves as a succinct review of pertinent updates and future directions regarding migraine. Read More

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00256196183071
Publisher Site
http://dx.doi.org/10.1016/j.mayocp.2018.09.006DOI Listing
November 2018
13 Reads

CGRP, Amylin, Immunology, and Headache Medicine.

Headache 2019 Jan 3;59(1):131-150. Epub 2018 Nov 3.

University of Minnesota Medical School, Minneapolis, MN, USA.

Background: Calcitonin gene-related peptide (CGRP) therapeutics introduce new excitement and possibly yet to be determined distressing discords in the field of Headache Medicine. Growth in knowledge of CGRP in the pathophysiology of migraine introduced CGRP antagonism to headache treatment. Potential adverse effects on the other circulatory and neurovascular diseases have been foremost concerns. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/head.13432
Publisher Site
http://dx.doi.org/10.1111/head.13432DOI Listing
January 2019
12 Reads

Diagnosis and Treatment of Primary Headache Disorders in Older Adults.

J Am Geriatr Soc 2018 Dec 25;66(12):2408-2416. Epub 2018 Sep 25.

Headache and Facial Pain Center, Department of Neurology and Rehabilitation Medicine, University of Cincinnati, Cincinnati, Ohio.

Objectives: To provide a unique perspective on geriatric headache and a number of novel treatment options that are not well known outside of the headache literature.

Design: Review of the most current and relevant headache literature for practitioners specializing in geriatric care.

Results: Evaluation and management of headache disorders in older adults requires an understanding of the underlying pathophysiology and how it relates to age-related physiological changes. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jgs.15586
Publisher Site
http://dx.doi.org/10.1111/jgs.15586DOI Listing
December 2018
16 Reads

History and Review of anti-Calcitonin Gene-Related Peptide (CGRP) Therapies: From Translational Research to Treatment.

Authors:
Stewart J Tepper

Headache 2018 Nov 22;58 Suppl 3:238-275. Epub 2018 Sep 22.

Professor of Neurology, Geisel School of Medicine at Dartmouth, Hanover, NH.

Objective - To briefly describe the history of and available data on anti-calcitonin gene-related peptide (CGRP) therapies for headache. Background - CGRP was proposed as a target for primary headache therapies. Translational research involved moving from delineating the relationships between CGRP and primary headaches and the clinical development of anti-CGRP treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13379DOI Listing
November 2018
4 Reads

Migraine and cluster headache - the common link.

J Headache Pain 2018 Sep 21;19(1):89. Epub 2018 Sep 21.

Department of Neurogeriatric Medicine, Headache Medical Center Linz, Ordensklinikum Linz Barmherzige Schwestern, Seilerstaette 4, 4010, Linz, Austria.

Although clinically distinguishable, migraine and cluster headache share prominent features such as unilateral pain, common pharmacological triggers such glyceryl trinitrate, histamine, calcitonin gene-related peptide (CGRP) and response to triptans and neuromodulation. Recent data also suggest efficacy of anti CGRP monoclonal antibodies in both migraine and cluster headache. While exact mechanisms behind both disorders remain to be fully understood, the trigeminovascular system represents one possible common pathophysiological pathway and network of both disorders. Read More

View Article

Download full-text PDF

Source
https://thejournalofheadacheandpain.biomedcentral.com/articl
Publisher Site
http://dx.doi.org/10.1186/s10194-018-0909-4DOI Listing
September 2018
22 Reads

The association between migraine and physical exercise.

J Headache Pain 2018 Sep 10;19(1):83. Epub 2018 Sep 10.

Department of Neuromedicine and Movement Science, NTNU Norwegian University of Science and Technology, Trondheim, Norway.

Background: There is an unmet need of pharmacological and non-pharmacological treatment options for migraine patients. Exercise can be used in the treatment of several pain conditions, including. However, what exact role exercise plays in migraine prevention is unclear. Read More

View Article

Download full-text PDF

Source
https://thejournalofheadacheandpain.biomedcentral.com/articl
Publisher Site
http://dx.doi.org/10.1186/s10194-018-0902-yDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134860PMC
September 2018
33 Reads

Antigens and Antibodies in Disease With Specifics About CGRP Immunology.

Headache 2018 Nov 5;58 Suppl 3:230-237. Epub 2018 Sep 5.

Department of Neurology, University of Minnesota Medical School, Minneapolis, MN, USA.

Growth in knowledge about calcitonin gene-related peptide (CGRP) in the pathophysiology of migraine brought CGRP antagonism to headache medicine. Failures in development of small molecule CGRP receptor antagonists and increasing knowledge and use of monoclonal antibodies (mAbs) in medicine led to the breakthrough development of large molecule anti-CGRP mAbs: eptinezumab, erenumab, fremanezumab, and galcanezumab. This specifics about CGRP immunology aims to outline: (1) knowledge needed for CGRP antagonism and (2) developmental issues of specific CGRP antagonists for provider use. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/head.13409
Publisher Site
http://dx.doi.org/10.1111/head.13409DOI Listing
November 2018
26 Reads

Vascular Contributions to Migraine: Time to Revisit?

Front Cell Neurosci 2018 3;12:233. Epub 2018 Aug 3.

Department of Molecular Physiology and Biophysics, University of Iowa, Iowa City, IA, United States.

Migraine is one of the most prevalent and disabling neurovascular disorders worldwide. However, despite the increase in awareness and research, the understanding of migraine pathophysiology and treatment options remain limited. For centuries, migraine was considered to be a vascular disorder. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fncel.2018.00233DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6088188PMC
August 2018
2 Reads

PACAP38 and PAC receptor blockade: a new target for headache?

J Headache Pain 2018 Aug 7;19(1):64. Epub 2018 Aug 7.

Department of Internal Medicine, Institute of Clinical Sciences, Lund University, Lund, Sweden.

Pituitary adenylate cyclase activating polypeptide-38 (PACAP38) is a widely distributed neuropeptide involved in neuroprotection, neurodevelopment, nociception and inflammation. Moreover, PACAP38 is a potent inducer of migraine-like attacks, but the mechanism behind this has not been fully elucidated.Migraine is a neurovascular disorder, recognized as the second most disabling disease. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-018-0893-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6081277PMC
August 2018
46 Reads

Cluster headache beyond the pain phase: A prospective study of 500 attacks.

Neurology 2018 Aug 27;91(9):e822-e831. Epub 2018 Jul 27.

From the Danish Headache Center, Department of Neurology (A.S., N.L., R.B., A.H., R.J., M.B.), Rigshospitalet-Glostrup, University of Copenhagen; and Department of Clinical Physiology and Nuclear Medicine (M.B.), Center for Functional and Diagnostic Imaging, Hvidovre Hospital, Copenhagen, Denmark.

Objective: To describe the nature, prevalence, and duration of symptoms in the preictal, ictal, and postictal phases of cluster headache (CH) attacks.

Methods: Fifty-seven patients with episodic or chronic CH participated in this prospective, observational study. In a questionnaire concerning 33 CH and migraine-related symptoms, patients reported the clinical features of up to 10 CH attacks/patient. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1212/01.wnl.0000542491.92981.03DOI Listing
August 2018
4 Reads

Emerging Treatments in Episodic Migraine.

Curr Pain Headache Rep 2018 Jul 16;22(9):61. Epub 2018 Jul 16.

Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA.

Purpose Of Review: The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine.

Recent Findings: Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options. A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT agonists, and PACAP receptor monoclonal antibodies. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11916-018-0716-2DOI Listing
July 2018
7 Reads

Peripherally administered calcitonin gene-related peptide induces spontaneous pain in mice: implications for migraine.

Pain 2018 Nov;159(11):2306-2317

Department of Molecular Physiology and Biophysics, University of Iowa Carver College of Medicine, University of Iowa, Iowa City, IA, United States.

Migraine is the third most common disease in the world (behind dental caries and tension-type headache) with an estimated global prevalence of 15%, yet its etiology remains poorly understood. Recent clinical trials have heralded the potential of therapeutic antibodies that block the actions of the neuropeptide calcitonin gene-related peptide (CGRP) or its receptor to prevent migraine. Calcitonin gene-related peptide is believed to contribute to trigeminal nerve hypersensitivity and photosensitivity in migraine, but a direct role in pain associated with migraine has not been established. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/j.pain.0000000000001337DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193822PMC
November 2018
8 Reads

Characterization of the trigeminovascular actions of several adenosine A receptor antagonists in an in vivo rat model of migraine.

J Headache Pain 2018 May 25;19(1):41. Epub 2018 May 25.

Division of Vascular Medicine and Pharmacology, Department of Internal Medicine, Erasmus MC, Rotterdam, Dr Molewaterplein 50, 3015, GE, Rotterdam, The Netherlands.

Background: Migraine is considered a neurovascular disorder, but its pathophysiological mechanisms are not yet fully understood. Adenosine has been shown to increase in plasma during migraine attacks and to induce vasodilation in several blood vessels; however, it remains unknown whether adenosine can interact with the trigeminovascular system. Moreover, caffeine, a non-selective adenosine receptor antagonist, is included in many over the counter anti-headache/migraine treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-018-0867-xDOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970128PMC
May 2018
9 Reads

Trigeminal ganglion transcriptome analysis in 2 rat models of medication-overuse headache reveals coherent and widespread induction of pronociceptive gene expression patterns.

Pain 2018 Oct;159(10):1980-1988

Department of Health Sciences, Section of Clinical Pharmacology and Oncology, University of Florence, Florence, Italy.

We attempted to gather information on the pathogenesis of medication-overuse headache, as well as on the neurochemical mechanisms through which symptomatic medication overuse concurs to headache chronification. Transcriptional profiles were therefore evaluated as an index of the homeostasis of the trigeminovascular system in the trigeminal ganglion of female rats exposed for 1 month to daily oral doses of eletriptan or indomethacin. We report that both drug treatments change trigeminal ganglion gene expression to a similar extend. Read More

View Article

Download full-text PDF

Source
http://Insights.ovid.com/crossref?an=00006396-201810000-0000
Publisher Site
http://dx.doi.org/10.1097/j.pain.0000000000001291DOI Listing
October 2018
6 Reads

A Review of Monoclonal Antibody Therapies and Other Preventative Treatments in Migraine.

Authors:
Uwe Reuter

Headache 2018 May;58 Suppl 1:48-59

Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.

Monoclonal antibodies targeting the calcitonin gene-related peptide pathway represent a new class of mechanism-specific, migraine-targeted therapies available for migraine prevention. To date, four monoclonal antibodies have demonstrated efficacy in phase II and III trials, significantly reducing migraine days per month versus placebo with rapid onset of action. While their efficacy may be considered similar to existing preventive options, their true value may lie in an improved tolerability profile, with high specificity and selectivity for the calcitonin gene-related peptide receptor or ligand reducing the potential for off-target binding and toxicity. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/head.13302DOI Listing
May 2018
11 Reads

CGRP as the target of new migraine therapies - successful translation from bench to clinic.

Nat Rev Neurol 2018 Jun;14(6):338-350

Department of Clinical Sciences, Division of Experimental Vascular Research, Lund University, Lund, Sweden.

Treatment of migraine is on the cusp of a new era with the development of drugs that target the trigeminal sensory neuropeptide calcitonin gene-related peptide (CGRP) or its receptor. Several of these drugs are expected to receive approval for use in migraine headache in 2018 and 2019. CGRP-related therapies offer considerable improvements over existing drugs as they are the first to be designed specifically to act on the trigeminal pain system, they are more specific and they seem to have few or no adverse effects. Read More

View Article

Download full-text PDF

Source
http://www.nature.com/articles/s41582-018-0003-1
Publisher Site
http://dx.doi.org/10.1038/s41582-018-0003-1DOI Listing
June 2018
98 Reads

Chronic migraine: A process of dysmodulation and sensitization.

Authors:
Min Su Shengyuan Yu

Mol Pain 2018 Jan-Dec;14:1744806918767697. Epub 2018 Apr 12.

1 Department of Neurology, Chinese PLA General Hospital, Beijing, China.

Chronic migraine is a common chronic daily headache featured by frequent headache attacks with at least 15 headache days per month, which brings great disease burden to both the sufferers and the society. Transformed from episodic migraine, the pathophysiology of chronic migraine is not fully understood, even though several risk factors have been associated with migraine progression. Recent studies have identified both structural and functional alterations in some brain regions of chronic migraine patients indicating that maladaptation of the top-down pain modulation and subsequent sensitization of trigeminal system may be important in the pathogenesis of chronic migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/1744806918767697DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5900816PMC
October 2018
2 Reads

CGRP Monoclonal Antibodies for the Preventative Treatment of Migraine.

Curr Pain Headache Rep 2018 Apr 6;22(5):38. Epub 2018 Apr 6.

Charité Universitätsmedizin Berlin, Department of Neurology, Charité Headache Center, Charitéplatz 1, 10117, Berlin, Germany.

Purpose Of Review: CGRP is a key neuropeptide in migraine pathophysiology. The blockade of the CGRP pathway at the side of the CGRP receptor of the CGRP peptide leads to the interruption of trigeminal nerve system-mediated headache syndromes such as migraine. Monoclonal antibodies (mAbs) targeting the CGRP pathway have been developed and are currently under investigation for episodic (EM) and chronic migraine (CM) prevention. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11916-018-0686-4DOI Listing
April 2018
7 Reads

Are Migraine and Tension-Type Headache Genetically Related? An Investigation of Twin Family Data.

Twin Res Hum Genet 2018 04;21(2):112-118

Department of Biological Psychology,Netherlands Twin Register,Vrije Universiteit,Amsterdam,The Netherlands.

Migraine and tension-type headache (TTH) are often viewed as distinct entities and defined as such in the International Classification of Headache Disorders, 2nd edition (ICHD-II) criteria, although there is also empirical evidence to suggest they may be etiologically similar. This study aims to investigate whether migraine and TTH are etiologically related conditions. First, we explored whether migraine and TTH were associated with the same environmental and lifestyle risk factors at the population level. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/thg.2018.5DOI Listing
April 2018
4 Reads

The Role of Endothelin in the Pathophysiology of Migraine-a Systematic Review.

Curr Pain Headache Rep 2018 Mar 19;22(4):27. Epub 2018 Mar 19.

Danish Headache Center and Department of Neurology, Rigshospitalet Glostrup, Faculty of Health and Medical Sciences, University of Copenhagen, Nordre Ringvej 57, DK-2600, Glostrup, Denmark.

Purpose Of Review: Vasoactive peptides play a key role in the attack-initiating cascade of migraine. Recent studies have highlighted a potentially important role for endothelin-1, a potent vasoconstrictor peptide, in migraine pathophysiology. Here, we review the current data on endothelin's involvement in migraine. Read More

View Article

Download full-text PDF

Source
http://link.springer.com/10.1007/s11916-018-0682-8
Publisher Site
http://dx.doi.org/10.1007/s11916-018-0682-8DOI Listing
March 2018
10 Reads

Targeted CGRP Small Molecule Antagonists for Acute Migraine Therapy.

Neurotherapeutics 2018 04;15(2):304-312

NIHR-Wellcome Trust, King's Clinical Research Facility, King's College Hospital, London, UK.

Migraine is a highly prevalent, severe, and disabling neurological condition with a significant unmet need for effective acute therapies. Patients (~50%) are dissatisfied with their currently available therapies. Calcitonin gene-related peptide (CGRP) has emerged as a key neuropeptide involved in the pathophysiology of migraines. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-018-0617-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935646PMC
April 2018
5 Reads

The big CGRP flood - sources, sinks and signalling sites in the trigeminovascular system.

Authors:
Karl Messlinger

J Headache Pain 2018 Mar 12;19(1):22. Epub 2018 Mar 12.

Institute of Physiology and Pathophysiology, Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsstr. 17, 91054, Erlangen, Germany.

Background: Calcitonin gene-related peptide (CGRP) has long been a focus of migraine research, since it turned out that inhibition of CGRP or CGRP receptors by antagonists or monoclonal IgG antibodies was therapeutic in frequent and chronic migraine. This contribution deals with the questions, from which sites CGRP is released, where it is drained and where it acts to cause its headache proliferating effects in the trigeminovascular system.

Results: The available literature suggests that the bulk of CGRP is released from trigeminal afferents both in meningeal tissues and at the first synapse in the spinal trigeminal nucleus. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-018-0848-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5847494PMC
March 2018
6 Reads

Current Treatment Options: Headache Related to Menopause-Diagnosis and Management.

Curr Treat Options Neurol 2018 Mar 6;20(4). Epub 2018 Mar 6.

Department of Neurology, Thomas Jefferson University, 900 Walnut St. Suite 200, Philadelphia, PA, 19107, USA.

Purpose Of Review: Menopause is a life-changing event in numerous ways. Many women with migraine hold hope that the transition to the climacteric state will coincide with a cessation or improvement of migraine. This assumption is based mainly on common lay perceptions as well as assertions from many in the healthcare community. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11940-018-0492-7DOI Listing
March 2018
6 Reads

ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.

Cephalalgia 2018 05 22;38(6):1026-1037. Epub 2018 Feb 22.

8 7129 Amgen Inc. , Thousand Oaks, CA, USA.

Background Calcitonin gene-related peptide plays an important role in migraine pathophysiology. Erenumab, a human monoclonal antibody that inhibits the calcitonin gene-related peptide receptor, is being evaluated for migraine prevention. Methods In this randomized, double-blind, placebo-controlled, phase 3 study, 577 adults with episodic migraine were randomized to placebo or 70 mg erenumab; 570 patients were included in efficacy analyses. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1177/0333102418759786DOI Listing
May 2018
10 Reads

Targeted Orexin and Hypothalamic Neuropeptides for Migraine.

Neurotherapeutics 2018 04;15(2):377-390

Department of Physiology, Faculty of Dentistry, Chulalongkorn University, Pathumwan, Bangkok, Thailand.

The hypothalamus is involved in the regulation of homeostatic mechanisms and migraine-related trigeminal nociception and as such has been hypothesized to play a central role in the migraine syndrome from the earliest stages of the attack. The hypothalamus hosts many key neuropeptide systems that have been postulated to play a role in this pathophysiology. Such neuropeptides include but are not exclusive too orexins, oxytocin, neuropeptide Y, and pituitary adenylate cyclase activating protein, which will be the focus of this review. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s13311-017-0602-3DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5935635PMC
April 2018
3 Reads

Recent Advances in Pharmacotherapy for Migraine Prevention: From Pathophysiology to New Drugs.

Drugs 2018 Mar;78(4):411-437

Headache Group, Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Migraine is a common and disabling neurological disorder, with a significant socioeconomic burden. Its pathophysiology involves abnormalities in complex neuronal networks, interacting at different levels of the central and peripheral nervous system, resulting in the constellation of symptoms characteristic of a migraine attack. Management of migraine is individualised and often necessitates the commencement of preventive medication. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40265-018-0865-yDOI Listing
March 2018
4 Reads

Effect of a calcitonin gene-related peptide-binding L-RNA aptamer on neuronal activity in the rat spinal trigeminal nucleus.

J Headache Pain 2018 Jan 15;19(1). Epub 2018 Jan 15.

Institute of Physiology and Pathophysiology, University of Erlangen-Nürnberg, Universitätstrasse 17, D-91054, Erlangen, Germany.

Background: Calcitonin gene-related peptide (CGRP) plays a major role in the pathogenesis of migraine and other primary headaches. Spinal trigeminal neurons integrate nociceptive afferent input from trigeminal tissues including intracranial afferents, and their activity is thought to reflect facial pain and headache in man. CGRP receptor inhibitors and anti-CGRP antibodies have been demonstrated to be therapeutically effective in migraine. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s10194-018-0832-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768576PMC
January 2018
10 Reads

Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab.

J Pain Res 2017 8;10:2751-2760. Epub 2017 Dec 8.

Department of Clinical and Molecular Medicine, Regional Referral Headache Center, Sant'Andrea Hospital, Sapienza University of Rome, Rome, Italy.

Migraine is a highly disabling neurological condition, and preventative treatment still remains problematic, due to aspecificity of the majority of the currently available prophylactic drugs. Calcitonin-gene-related peptide (CGRP) plays a crucial role in migraine pathophysiology; agents aimed at blocking its activity have, therefore, been developed in recent years, among which are monoclonal antibodies (mAbs) against CGRP, to prevent migraine. Erenumab is the only mAb that targets the CGRP receptor instead of the ligand, with high specificity and affinity of binding. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2147/JPR.S128143DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5727105PMC
December 2017
10 Reads

Side effects associated with current and prospective antimigraine pharmacotherapies.

Expert Opin Drug Metab Toxicol 2018 Jan 15;14(1):25-41. Epub 2017 Dec 15.

d Departamento de Farmacobiología , Cinvestav-Coapa , Ciudad de México , México.

Introduction: Migraine is a neurovascular disorder. Current acute specific antimigraine pharmacotherapies target trigeminovascular 5-HT, 5-HT and CGRP receptors but, unfortunately, they induce some cardiovascular and central side effects that lead to poor treatment adherence/compliance. Therefore, new antimigraine drugs are being explored. Read More

View Article

Download full-text PDF

Source
https://www.tandfonline.com/doi/full/10.1080/17425255.2018.1
Publisher Site
http://dx.doi.org/10.1080/17425255.2018.1416097DOI Listing
January 2018
21 Reads

Dysautonomia in the pathogenesis of migraine.

Expert Rev Neurother 2018 02 13;18(2):153-165. Epub 2017 Dec 13.

a Department of Health Science and Technology, Faculty of Medicine , Aalborg University , Aalborg , Denmark.

Introduction: Migraine is a common complex neurological disorder involving multiple brain areas that regulate autonomic, affective, cognitive, and sensory functions. This review explores autonomic nervous system (ANS) dysfunction in migraine headache sufferers. Areas covered: Reference material for this review was obtained through PubMed searches. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/14737175.2018.1414601DOI Listing
February 2018
6 Reads

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the CGRP Binding Monoclonal Antibody LY2951742 (Galcanezumab) in Healthy Volunteers.

Front Pharmacol 2017 17;8:740. Epub 2017 Oct 17.

Center for Clinical Pharmacology, University Hospitals of Leuven, KU Leuven, Leuven, Belgium.

Calcitonin gene-related peptide (CGRP) is pivotal in the pathophysiology of migraine headaches and represents a promising target for migraine treatment. The humanized monoclonal antibody galcanezumab (LY2951742) binds to CGRP and may be effective in migraine prophylaxis. The primary objective was to evaluate the safety and tolerability of single and multiple doses of galcanezumab in humans. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fphar.2017.00740DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5651004PMC
October 2017
15 Reads

Nociceptive blink reflex habituation biofeedback in migraine.

Funct Neurol 2017 Jul/Sep;32(3):123-130

Reduced habituation of the nociceptive blink reflex (NBR) is considered a trait marker for genetic predisposition to migraine. In this open-label randomized controlled study, we aimed to test the efficacy of a biofeedback training based on learning of habituation of the NBR (NBR biofeedback) compared with pharmacological (topiramate) treatment and NBR biofeedback plus topiramate treatment in a cohort of migraine without aura patients eligible for prophylaxis. Thirty-three migraine patients were randomly assigned to three months of treatment with: 1) NBR biofeedback, 2) NBR biofeedback plus topiramate 50 mg (b. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5726347PMC
June 2018
4 Reads